Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL12480668

NC(=O)c1cccc(OC(F)(F)F)c1.O=C(O)C(F)(F)F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.54
TNKS O95271 1/20 0.51
PARP15 Q460N3 1/20 0.51
PARP14 Q460N5 1/20 0.51
PARP10 Q53GL7 1/20 0.51
TNKS2 Q9H2K2 1/20 0.51
PARP2 Q9UGN5 1/20 0.51
ABL1 P00519 5/20 0.50
BCR P11274 3/20 0.50
KAT6A Q92794 2/20 0.50
DYRK1A Q13627 1/20 0.50
RIPK1 Q13546 1/20 0.48
TRPM8 Q7Z2W7 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
TAS1R2 Q8TE23 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29448761 0.94 PARP1 (0.61) PARP1TNKSPARP15PARP14PARP10
SCHEMBL711132 0.94 PARP1 (0.61) PARP1TNKSPARP15PARP14PARP10
Hydrochloric Acid SCHEMBL1268771 0.92 PARP1 (0.59) PARP1TNKSPARP15PARP14PARP10
Trifluoroacetic Acid SCHEMBL28214522 0.84 PARP1 (0.78) PARP1TNKSPARP15PARP14PARP10
SCHEMBL3722117 0.84 DYRK1A (0.62) PARP1TNKSPARP15PARP14PARP10
Trifluoroacetic Acid SCHEMBL29713373 0.83 PARP1 (0.59) PARP1TNKSPARP15PARP14PARP10
Trifluoroacetic Acid SCHEMBL10277408 0.83 PARP1 (0.59) PARP1TNKSPARP15PARP14PARP10
SCHEMBL29459930 0.82 MRGPRX4 (0.61) KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4
SCHEMBL496275 0.82 MRGPRX4 (0.61) KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4
Trifluoroacetic Acid SCHEMBL12480672 0.81 NOTUM (0.47) KAT6AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
CN-103402996-B Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) NOVARTIS AG 2015-02-11 CN disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 PARP1 1468/4885TNKS 1806/4885PARP15 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.